Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: AZD1305

Study type: Interventional

Funder types: Industry

Identifiers

NCT00688831

D3190C00002

Details and patient eligibility

About

The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body

Enrollment: 36 patients

Sex: Male

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers
• BIM 19-30 kg/m2

Exclusion criteria

• Potassium outside normal reference values
• ECG findings outside normal range

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

36 participants in 2 patient groups, including a placebo group

A

Experimental group

Description:

AZD1305 solution for iv infusion

Treatment:

Drug: AZD1305

B

Placebo Comparator group

Description:

NaCl solution for iv infusion

Treatment:

Drug: Placebo